- Home
- MEGI vs COGT Comparison
MEGI vs COGT Comparison
Compare MEGI & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEGI
- COGT
- Stock Information
- Founded
- MEGI 2021
- COGT 2014
- Country
- MEGI United States
- COGT United States
- Employees
- MEGI N/A
- COGT N/A
- Industry
- MEGI Investment Managers
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- MEGI Finance
- COGT Health Care
- Exchange
- MEGI Nasdaq
- COGT Nasdaq
- Market Cap
- MEGI 729.7M
- COGT 817.5M
- IPO Year
- MEGI N/A
- COGT 2018
- Fundamental
- Price
- MEGI $14.12
- COGT $11.19
- Analyst Decision
- MEGI
- COGT Strong Buy
- Analyst Count
- MEGI 0
- COGT 9
- Target Price
- MEGI N/A
- COGT $19.38
- AVG Volume (30 Days)
- MEGI 178.0K
- COGT 4.7M
- Earning Date
- MEGI 01-01-0001
- COGT 08-05-2025
- Dividend Yield
- MEGI 11.40%
- COGT N/A
- EPS Growth
- MEGI N/A
- COGT N/A
- EPS
- MEGI N/A
- COGT N/A
- Revenue
- MEGI N/A
- COGT N/A
- Revenue This Year
- MEGI N/A
- COGT N/A
- Revenue Next Year
- MEGI N/A
- COGT N/A
- P/E Ratio
- MEGI N/A
- COGT N/A
- Revenue Growth
- MEGI N/A
- COGT N/A
- 52 Week Low
- MEGI $10.63
- COGT $3.72
- 52 Week High
- MEGI $14.89
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- MEGI 50.98
- COGT 87.74
- Support Level
- MEGI $13.95
- COGT $7.07
- Resistance Level
- MEGI $14.41
- COGT $10.23
- Average True Range (ATR)
- MEGI 0.20
- COGT 0.66
- MACD
- MEGI -0.03
- COGT 0.37
- Stochastic Oscillator
- MEGI 32.08
- COGT 99.89
About MEGI MainStay CBRE Global Infrastructure Megatrends Term Fund
NYLI CBRE Global Infrastructure Megatrends Term Fund is a non-diversified, closed-end management investment company. The Fund's investment objective is to seek a high level of total return with an emphasis on current income. It is focused on the investment megatrends of decarbonization, digital transformation and asset modernization, which are reshaping the demand for infrastructure assets and driving income and growth potential.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.